Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Giulia Bianchi"'
Autor:
Laura Pizzuti, Laura Cortesi, Barbara Tagliaferri, Armando Santoro, Patrizia Vici, A. Gambaro, Rita De Sanctis, Raffaella Palumbo, Alessandra Fabi, Vita Leonardi, Rosalba Torrisi, Maria Rosaria Valerio, Rossana Gueli, Marina Elena Cazzaniga, Giulia Bianchi
Publikováno v:
Breast Cancer Research and Treatment. 190:103-109
Purpose: The most appropriate therapy for HR + /HER2-positive (HER2 +) advanced breast cancer (ABC) is a matter of debate. Co-targeting of both receptors represents an attractive strategy to overcome the cross-talk between them. Methods: The HERMIONE
Autor:
Do-Youn Oh, Barbara Galbardi, Ling-Ming Tseng, Young-Hyuck Im, Tadeusz Pienkowski, Serena Di Cosimo, Giulia Viale, M. Dugo, Vladimir Semiglazov, Loris De Cecco, Begoña Bermejo, Elda Tagliabue, Luca Gianni, Juan de la Haba-Rodriguez, Giulia Bianchi, Mei-Ching Liu, Brigitte Poirier, Tiziana Triulzi, Pinuccia Valagussa, Giampaolo Bianchini
Publikováno v:
Molecular oncology. 16(12)
As most erb-b2 receptor tyrosine kinase 2 (HER2)-positive breast cancer (BC) patients currently receive dual HER2-targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting post-surgical salvage t
Autor:
Gabriella Mariani, Emma Zattarin, Rita Leporati, Giovanni Fucà, Riccardo Lobefaro, Claudio Vernieri, Francesca Ligorio, Giulia Bianchi, Filippo de Braud, Giuseppe Capri, Carmen G. Rea, Luca Zambelli
Publikováno v:
Cancers
Volume 13
Issue 8
Cancers, Vol 13, Iss 1964, p 1964 (2021)
Volume 13
Issue 8
Cancers, Vol 13, Iss 1964, p 1964 (2021)
Different peripheral blood parameters have emerged as prognostic biomarkers in breast cancer (BC), but their predictive role in Human Epidermal growth factor Receptor 2 positive (HER2+) advanced BC (aBC) patients receiving dual anti-HER2 blockade rem
Autor:
G.L. De Salvo, G. Moretti, Patricia Galván, Maria Vittoria Dieci, Giancarlo Bisagni, R. Vicini, Gaia Griguolo, Giulia Bianchi, Aleix Prat, Massimo Ambroggi, Tomás Pascual, Laia Paré, Loredana Urso, Antonio Frassoldati, Carlo Alberto Giorgi, Pierfranco Conte, Enrico Orvieto, Valentina Guarneri
Publikováno v:
Annals of Oncology
Background In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus neg
Autor:
Alba Fiorentino, Francesca Di Salvo, F. Bonfantini, Valentina Maria Riboldi, Riccardo Valdagni, Milena Sant, V. Cosentino, Laura Lozza, Massimiliano Gennaro, Maria De Santis, Emanuele Pignoli, Serena Di Cosimo, Giulia Bianchi
Publikováno v:
Clinical Breast Cancer. 18:e363-e371
The purpose of this study was to examine the impact of trastuzumab on acute skin and cardiac toxicity in patients with breast cancer treated with chemotherapy with or without trastuzumab and adjuvant whole breast hypofractionated radiotherapy (hypo-R
Autor:
Luigi Celio, Giulia Bianchi, Claudio Vernieri, Monica Milano, Maria Silvia Cona, Marta Brambilla, Filippo de Braud, Claudia Maggi, Gabriella Mariani, Giuseppe Capri, Chiara Fabbroni, Alessia Mennitto, Michele Prisciandaro
Publikováno v:
Critical reviews in oncology/hematology. 139
HER2-positive breast cancer (HER2 + BC) represents 15–20% of all BCs. In the last two decades, the introduction of monoclonal antibodies (MoAbs), tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs) directed against HER2 impressive
Autor:
Fabio Puglisi, Daniele Generali, Caterina Fontanella, Ilaria Portarena, Paolo Marchetti, Giulia Bianchi, Vito Amoroso, Antonio Grassadonia, Lorenzo Gianni, Andrea Fontana, Emanuela Rossi, Giancarlo Bisagni, Luca Moscetti, Cristina Falci
Publikováno v:
Critical Reviews in Oncology/Hematology. 98:211-221
The introduction of trastuzumab into routine clinical practice has had a dramatic effect on the outlook for patients with HER2-positive breast cancer. Nevertheless, answers to some long unresolved questions about the optimal use of trastuzumab (such
Autor:
Marta Brambilla, Filippo de Braud, Giuseppe Capri, Giulia Bianchi, Lorenzo Castagnoli, Andrea Vingiani, Daniele Generali, Elda Tagliabue, Angela Maria Rizzo, Tiziana Triulzi, Claudio Vernieri, Paola Antonia Corsetto, Antonino Belfiore, Francesca Corti, Serenella M. Pupa, Giancarlo Pruneri, Francesca Ligorio, Elena Fasano, Simona Faraci
Publikováno v:
Cancer Research. 80:P3-02
Background: Although anti-HER2 treatments, including the monoclonal antibodies trastuzumab (T) and pertuzumab (P) and the tyrosine kinase inhibitor lapatinib (L), have remarkably improved the prognosis of patients with HER2-positive breast cancer (HE
Autor:
Gabriella Mariani, Silvia Damian, Angela Moliterni, Matteo Duca, Giulia Bianchi, Laura Ferrari, Sara Cresta, Stefano Cavalieri, Filippo de Braud, Giuseppe Capri, Pinuccia Valagussa, Giulia Galli
Publikováno v:
The breast journal. 25(2)
The efficacy of anthracycline- and taxane-based chemotherapy for perioperative treatment of breast cancer (BC) has been established. No superiority of a cytotoxic regimen has been demonstrated, provided that administration of an anthracycline and a t
Publikováno v:
Future oncology (London, England). 12(11)
The transmembrane tyrosine kinase receptor HER2 is overexpressed in 20% of invasive breast cancers and is associated with more aggressive disease. Until the advent of targeted agents, HER2 was associated with worse outcome. Trastuzumab, a recombinant